explore -WSS

explore

author：hotspot 2025-09-30 00:48:39 - browse：985

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： What the airline industry can learn from medicine

Wikipedia

WSS

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Medicare drug price negotiation hearing pits pharma v Biden admin

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

$1 billion proposal to grow Boston, Massachusetts biotech

The untold story of TV’s first prescription drug ad

First over

hotspot

explore

entertainment

In Memoriam: Notable people who died in 2023

‘Oppenheimer’ and the risks of AI in health care

In age of alternative facts, a scholarly course on calling out crap

Scientists inch closer to single

Hepatitis C has a cure — but many Americans still lack access to it

Adults seen as increasingly susceptible to measles

Medical leaders decry Supreme Court decision on affirmative action

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Supreme Court strikes down use of affirmative action

Harvard's David Sinclair gets blowback over aging

knowledge

Scientists inch closer to single

The high personal cost of affirmative action for Black doctors

Sage hopes for a blockbuster in antidepressant now before FDA

The public health thinking behind the CDC’s new Covid guidance

Families look for replacement for GSK asthma drug Flovent

Mega Millions pot grows to $1.25 billion after no winner

hotspot

entertainment

Wikipedia

focus